Biotech

All Articles

Zephyrm finds Hong Kong IPO to fund phase 3 cell treatment tests

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, filing (PDF) for an IPO t...

Frazier Lifestyle Sciences gets $630M for little, mid-cap biotechs

.Frazier Lifespan Sciences has actually sourced a further $630 million for its fund focused on littl...

GigaGen amasses around $135M BARDA money to hammer botox

.Antitoxin fanatic GigaGen, a subsidiary of Spanish biopharma Grifols, is ramping up its specialist ...

GPCR firm Septerna declare IPO on toughness of preclinical data

.Septerna is about to find out just how a biotech without "any sort of relevant scientific data" mea...

Kurma finalizes initially $154M loot for biggest biotech fund yet

.European VC agency Kurma Allies has unveiled its latest biotech fund, with 140 thousand europeans (...

Prothena advertises one officer while one more places-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of notable leadership hirings, firings as we...

Editas profit Vertex Cas9 licensing civil liberties for $57M

.Versus the scenery of a Cas9 patent battle that declines to pass away, Editas Medication is cashing...

Ultragenyx tweaks genetics therapy dosing to call up efficiency

.A minority of people taking Ultragenyx Pharmaceutical's Wilson disease genetics treatment UX701 hav...

Biopharma unemployment fee maintains in Q3: Fierce Biotech review

.As summertime warm looks to cool down winds, wishes that this year would take widespread business c...

J &amp J goes down stage 2 dengue prospect in most recent switch from vaccinations

.Johnson &amp Johnson's deprioritization of its contagious ailment pipeline has professed one more p...